Neuroprotective effects of intraoperative dexmedetomidine versus saline infusion combined with goal-directed haemodynamic therapy for patients undergoing cranial surgery

Abstract

BACKGROUND By inhibiting neuroinflammation dexmedetomidine may be neuroprotective in patients undergoing cranial surgery, but it reduces cardiac output and cerebral blood flow. OBJECTIVE To investigate whether intra-operative dexmedetomidine combined with goal-directed haemodynamic therapy (GDHT) has neuroprotective effects in cranial surgery. DESIGN A double-blind, single-institution, randomised controlled trial. SETTING A single university hospital, from April 2017 to April 2020. PATIENTS A total of 160 adults undergoing elective cranial surgery. INTERVENTION Infusion of dexmedetomidine (0.5 μg kg−1 h−1) or saline combined with GDHT to optimise stroke volume during surgery. MAIN OUTCOME MEASURES The proportion who developed postoperative neurological complications was compared. Postoperative disability was assessed using the Barthel Index at time points between admission and discharge, and also the 30-day modified Rankin Scale (mRS). Postoperative delirium was assessed. The concentration of a peri-operative serum neuroinflammatory mediator, high-mobility group box 1 protein (HMGB1), was compared. RESULTS Fewer patients in the dexmedetomidine group developed new postoperative neurological complications (26.3% vs. 43.8%; P = 0.031), but the number of patients developing severe neurological complications was comparable between the two groups (11.3% vs. 20.0%; P = 0.191). In the dexmedetomidine group the Barthel Index reduction [0 (−10 to 0)] was less than that in the control group [−5 (−15 to 0)]; P = 0.023, and there was a more favourable 30-day mRS (P = 0.013) with more patients without postoperative delirium (84.6% vs. 64.2%; P = 0.012). Furthermore, dexmedetomidine induced a significant reduction in peri-operative serum HMGB1 level from the baseline (222.5 ± 408.3 pg ml−1) to the first postoperative day (152.2 ± 280.0 pg ml−1) P = 0.0033. There was no significant change in the control group. The dexmedetomidine group had a lower cardiac index than did the control group (3.0 ± 0.8 vs. 3.4 ± 1.8 l min−1 m−2; P = 0.0482) without lactate accumulation. CONCLUSIONS Dexmedetomidine infusion combined with GDHT may mitigate neuroinflammation without undesirable haemodynamic effects during cranial surgery and therefore be neuroprotective. TRIAL REGISTRATION Clinicaltrials.gov Identifier: NCT02878707

Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis

“…Most of the trials did not report on our outcomes. A total of 106 RCTs and one sub‐study of an included RCT provided data for quantitative synthesis 43–149 . Six of the included trials reported a total of 15 eligible comparisons 60,62,82,124,145,147 .…”

Effects of Goal-Directed Hemodynamic Therapy Using a Noninvasive Finger-Cuff Monitoring Device on Intraoperative Cerebral Oxygenation and Early Delayed Neurocognitive Recovery in Patients Undergoing Beach Chair Position Shoulder Surgery: A Randomized Controlled Trial

“…The decision to administer the Voluven was based on a ≥5% increase in the stroke volume index after a minifluid challenge test (100 mL crystalloid infusion within 1 minute). 11,12 A minifluid challenge test has a fluid responsiveness detection accuracy superior to that of stroke volume variation; therefore, it was applied to the GDHT group to achieve cardiac output optimization more efficiently. By comparison, the institutional fluid protocol was applied to the patients in the control group; this protocol comprised urine output replacement with crystalloid infusion and maintenance of stroke volume variation at <13% with crystalloid or colloid at attending anesthesiologist’s discretion.…”

Perioperative stroke: A perspective on challenges and opportunities for experimental treatment and diagnostic strategies

“…However, due to its broad sedative, anxiolytic, analgesic, sympatholytic, and stable hemodynamic profile, dexmedetomidine is now used as an adjuvant for premedication, especially in patients susceptible to preoperative and perioperative stress. More importantly, dexmedetomidine improves cognition after carotid endarterectomy, 91 reduces postoperative delirium after joint replacement surgery, 92 and attenuates postoperative disability after cranial surgery 93 pointing at its potential neuroprotective properties in a perioperative setting. Dexmedetomidine also reduces inflammatory factor expression and enhanced brain-derived neurotrophic factor (BDNF) levels.…”